ATXS - Earnings call transcript Q3 2021 | Astria Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Q3 2021 Astria Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today, Andrea Matthews, Senior Vice President, Corporate Affairs. ahead. go Please

Andrea Matthews

Jill Welcome we Elisa. our Astria conference Andrew today Therapeutics quarter Nichols, Officer; Thank Scientific Chief provide to a where Officer; are; me With will financial review Chief corporate call, Executive XXXX Andy you, results. today’s Milne, call, update third Komjathy, reference financial summarizing is Officer. update our and issued Chief and Noah on results, press website. a our Financial Officer; Chief and XXXX which corporate will we release today’s Commercial QX our on Clauser, We this available and morning,

publicly the financial wrap Jill data provide with result corporate recent Jill, using Noah as HAE potential X, We’re that over website. statements Andy note Form future call judgment our as any of available applicable statements are differ subsequent in Jill? will on forward-looking from expectations SEC today well let available to related we I an law. & based need things recent those under during indicated the results me also important Astria on will update. in Andrew uncertainties filings the update treatments risks, the annual section new Slide preclinical With discussions to to risks our follow our required those Securities like and factors during the slides STAR-XXXX, make by current most then discussed and are statements pass as today’s of no for will which today’s statements statements Laws a will call Presentation a and business considered may these our Such on would may our within call, will up. other be Regulations. and that in Actual Investors’ as on and of to obligation uncertainties, materially of report represent part that, that update. by the on including except Events overview XX-K, mentioned variety our of forward-looking and of as provide undertakes share who’ll as website.

Jill Milne

you Thank morning, call. you, Andrea. joining and us today’s for everyone on Good thank

to to Turning Therapeutics. excited I’m introduce Astria Slide X,

patients embodies we that our commitment company all to put name first in Our do.

the from reflecting that us guide the comes Greek word Astria patients our are star, and that for us stars purpose. give

Our patients and that Astria are mission an life-changing the niche to by X, and see of will is affected Slide rare bring hope to diseases. immunological overview therapies with allergic On and you opportunity. investment families

kallikrein antibody a to be to opportunity we product angioedema is are lead that STAR-XXXX as treat living the a HAE. with preventative developing our develop patients plasma therapy We of STAR-XXXX Our or for program, exciting to inhibitor patient-friendly an hereditary monoclonal HAE. see most potential with

for XXXX on XXXX. to clinical This we potential STAR-XXXX. milestones, of the upcoming filing expect profile clinical by proof-of-concept clinical trial results in and track first demonstrate are for trial the differentiated mid important For initial IND an year end has

rare and opportunities the a with immunological allergic needs our niche goal broader are with to of also of addressing evaluating We and unmet expand diseases. patients pipeline

operating We position strong backed million, in were equivalents is of with we cash current Board sciences’ cash have the through experienced $XXX.X by to plan of QX, XXXX. At and Directors expected life team investors. a the of fund an and close leading which

symbol, on overview outstanding NASDAQ. We an X the provides and corporate updates on we today’s program as-basis of highlights. trade ATXS, under and have STAR-XXXX Slide XX.X million common shares an Astria

and track progress the with end good for XXXX. X We year initial program, are very are expected result Phase clinical making on by

long Immunology Allergy, YTE STAR-XXXX’s at site binding the duration potency, will preclinical Scientific review new enable and shortly. College American use of Scientific Officer, results and of Asthma action binding affinity, and Chief a data these regarding Our presented Annual week of Andy he Meeting, Nichols modifications last to

findings Officer burdens Komjathy, for National Commercial our for potential will in market our and STAR-XXXX Andrew opportunity at we Chief of the the HAE, disease the which on supporting our highlight patient presented to Next, Summit give and last month, substantial treatment our and Noah financials. Subsequently, update Officer, treatment the Financial burden. decrease Disorders Chief need an on Rare Organization Clauser, will disease

The burden. there and have For and the the severe, deficiency Patients an contact and to of affected life-changing occur lower with United the a burden important characterized disease in those edema significant is is X and in by blood how as a function with and an approximately patients the unpredictable, of in healthy with exists fear stress in for the get large a $X.X of the body’s abdomen therapies impacted life-threatening CX $X kallikrein such therapies treatment an debilitating Slide inhibitor of blocks kallikrein. inhibitor, by runaway HAE, is HAE provides without a called pathway. by you for holding is painful in of attacks a people HAE than CX on-demand between which individual, is inhibitor. is illustrates what a either or is HAE to production which absent with pathway, from inhibitor, external differences called attack, kallikrein system goal treatments aims In HAE more is or the a There inhibitor, no plasma preventative treatments most frequency are estimated In rare defective. plasma in the CX caused to And This tissue airway. to and most need With HAE of results grow treated in by patients break attack that occurs. it’s XXXX. damage a bradykinin continues an and a kallikrein be skin, plasma maybe produce patient by It bradykinin shows Unmet blood plasma plasma reducing XXXX our inhibiting STAR-XXXX, swelling. attacks component Slide for less HAE, live vessel reduce the kallikrein. with whereby active HAE X,XXX X pathological pressure inhibited. production plasma and billion is familiar global from market of preventative The CX healthy contact billion protein vessel effective which disease. an triggers kept States. to in patients, for and kallikrein. pain. preventing individuals introduction. is protein healthy to absence HAE Thereby, check edema an sometimes and In tool, by CX STAR-XXXX a and edema. prevent leads Even can to in when

has therapeutic see will immensely. recent that landscape positive On Friday, recently HAE changed plasma the the evolved inhibitors. a – the with Over entrance the years, kallikrein you of direction the landscape that for in

as unmet more patients was and physicians, that an HAE in interest than effective, XX% inhibitors infrequent remains there there dosing. on We plasma patients kallikrein of treatment approved still experience with However, option need high both preventative from heard attacks.

present We what are designed a needs patient’s HAE dosing We the aiming vision addressing at potential Slide treatment efficacy HAE with experience the patient-friendly, of over data caused patients it that with HAE. to Andy, a protection treatment generated to painful, that with STAR-XXXX a of as exciting plasma aspects that existing I’ll we and for the an inhibitor to determine clear could recent now our STAR-XXXX give from On with living key attacks STAR-XXXX hand are antibody patients. our based frequency STAR-XXXX deliver is aimed profile to depth kallikrein landscape. and develop Andy? are the HAE most and provide HAE. and long-acting, option life-threatening opportunity today an STAR-XXXX. the What’s X, treatment effective by recurrent more on preventative findings. as was think monoclonal in and its exciting developing see that be at the sometimes to look We is HAE of to treat

Andy Nichols

Allergy, Immunology is Last in pharmacokinetics week some described data Annual Jill. at Meeting poster Asthma of the pharmacology this I and our and a the preclinical describing Scientific on of website. STAR-XXXX and presented that College American the available Orleans, New Thanks,

binding estimated been that and binds vitro high XX, Turning plasma half-life of plasma shown efficacy We prevention have to STAR-XXXX than the In about words, different concentration of assay use characterize that STAR-XXXX weight Note, that the kallikrein from release affinity, kallikrein. by physiologically HAE exact relevant to a as be in used kininogen kallikrein molecular affinity site for other the we with the to HAE than of in high To use In attacks. kallikrein biochemistry same an drivers the lanadelumab. circulating STAR-XXXX, drives level catalyzed more key molecular in attack. to range HAE show assay the lanadelumab. a what bradykinin on bind And weight present that functional is follows an plasma showed Slide plasma vitro kininogen high of being experiments, is plasma of to kallikrein the binding competition tenfold to plasma the we potently potency of the plasma in the in attack. is that during in similar be concentration humans.

that translates by binding Because assay. XX% actually looked functional improvement STAR-XXXX have potency we kallikrein Importantly, the kallikrein believed of inhibition in to HAE that assay, efficacy. of XX%. be in consistent plasma with the clinical physiologically levels this over been that of of level inhibition to In tenfold into that assay kallikrein of is We potency STAR-XXXX is have about plasma of been potency concentration this therapeutically in high for to the the shown lanadelumab activity. attacks. relevant required lanadelumab high in affinity at to this has see inhibit be antibody the The relevant results prevent reported plasma

a half-lives half-life XX, YTE of the non-human extension STAR-XXXX. XX STAR-XXXX been Slide used introduction to modifications I the technology enable to information the in plasma XX about primates extend half-life designed being have of YTE in duration to shown extend were and to with of monoclonal The with antibodies days. Moving also other action. presented modifications long half-life

antibodies clinic XXX been have have have modifications that half-lives there addition, to the and XX of with in humans YTE been several have to in days. reported been In

is FcRn white more and YTE look half-life more given when parental at below a is means, kallikrein. begin that other non-human week, non-human of STAR-XXXX lanadelumab, same as three left the – lanadelumab, compared the that for the duration Together, three-fold antibody to or for in the we binding dosed, data enabled of functional infrequent for longer last by XX, levels to these can primates, efficacy, of for primates. below we panel XX. at its of plasma the say you with remained the at translated as in dose. antibodies for longer concentration the relative On XX the days plasma And about In than the results for level full STAR-XXXX increase a days the possibly the with from we are than potential panel can months approximately the the XX% the three-fold modifications. Slide assay enhanced than without in by as shown antibodies and day threshold fall targeting In the ICXX more predicted the In above inhibition humans in pharmacokinetics therapeutic potential STAR-XXXX antibody the that XX in plasma vitro same you support modifications. half-life the modifications dosing after longer. at YTE that than contrast, As of of the suggested the every potential XX YTE each both doses STAR-XXXX pH-dependent which This the half-life to see given experiments. plasma middle fall the duration minimum therapeutic days can levels understand by the

the a positive synthesizes is way. same see that right-hand model the plasma different concentration PK/PD together panel, kallikrein you is expected in at in data experiment. but each points that the the in time the the of of antibody percent What of Lastly, can a inhibition pharmacokinetic

The underway. through lanadelumab, have STAR-XXXX out supply and kallikrein In commercialization an in identified line kallikrein expected STAR-XXXX XX significantly high-producing X be has contrast, inhibition are plasma and plasma below for of dosing, extended same that following the potential the significant falls experience And fully be of and and by STAR-XXXX plasma data a by longer day to of appropriate XX XX of and preclinical we see Phase day antibody, that purposes intense predicted action. these about duration for level development all These studies. than kallikrein development therapeutics, cell days can to STAR-XXXX with have a an CDMO with potency the that is to inhibited. of You formulation. a the show proprietary increased inhibition duration that Working XX% is has bio our be same will planned of is non-clinical antibody enable dose a action lanadelumab, and to for and XX%.

Our Phase under all plans Slide of and GLP study the on differentiated an initiate see STAR-XXXX. we clinical terms next STAR-XXXX are We We proof-of-concept this first an for to shortly for volunteers. toxicology in establish Based this, profile progress, expect mid thereafter. trial and assays of X program first development. design. is to for STAR-XXXX to activity pharmacological for pharmacodynamic the opportunity relevant in informative the IND in our trial will be clinical program at XX, half-life file clinical in we outlines anticipate our clinical anticipate that year healthy

determine utilize pharmacodynamics safety, a to and pharmacokinetics We plasma assay biomarker will assess inhibition. kallikrein monitor

half-life, prolonged are trial from data safety, extended the year the this we of next are and first of XXXX. time dose data full the trial. kallikrein to with trial on And summary, pharmacodynamic will available. patients. to dosing period the plasma subjects Due has establish regimen refine cohorts end will STAR-XXXX, been positive, long with patient-friendly, to this most high extended before If opportunity this XX, show Initial and objective treated believe levels In set expected antibody treatment And to the and a Slide the antibody. achieved from HAE this half-life by for lanadelumab, follow for that the an expected the will for to Our goals pharmacokinetic our identify we demonstrate for the activity inhibitory has preventative STAR-XXXX of for same first profile that differentiated the option preclinically. our be but inhibit be was trial plasma less as could to STAR-XXXX. kallikrein the stage potency STAR-XXXX

a objective allowing and engineer period plasma This with of half-life, an preventing long a dosing potentially preclinically. was The for has less also to antibody frequent long for achieved time. second attacks been

therapy differentiated next in prevent over the are hand profile period community. in we to The new With patients of aiming now that a treatment a the trusted Andrew? to using demonstrate is with of it Andrew, attacks to to step extended this, needs time. important an I’ll of the to to modality HAE over provide clinic. HAE differentiated STAR-XXXX speak

Andrew Komjathy

both findings seeking switching suggest based as much convenient came treatment to The severe findings trying patients treatment open burden has for frequent new Patients Thanks, burden are Andy to for in not HAE satisfied their both I often participating showing patients administration. the been or as publications the and that improved Patients inclusion treatment HAE there an a attacks, were interested for therapies as that findings disease last their options and most On XX, corresponding at the preventative HAE everyone. reduce also that that could well Slide self-identified of treatments, represented these treatment and with patients depression. physicians. II. in morning, moderate many and are guidance. have patients on continue existing anxiety experience good emphasized Conference from HAE two for need address On somewhat need and are we to recent HAE highlight options from needs. treatment interview preventative Physicians These to screened Slide interviews structured is patients were as burden. and type, clinical a know that trials. severity, on Types like burden three recent NORD eligibility Disease tried future disease I’d month, average, treatment. using the XX, highlight and more in from decrease to On are disease that to

interviewed would of attacks patients the therapy that future I’ll always. patients or All Additionally, update. Noah, over offered frequent switch new from think less to about with on a competitive being provide it preventative dosing. there often turn financial be current if half despite efficacy shared treatment, their therapy, a to now similar

Noah Clauser

morning, good and everyone. Andrew Thanks,

Slide on provide to brief XX, Turning a financials I our will summary.

XXth, equivalents. million $XXX.X of September had cash we of and As cash XXXX,

We XXXX. sufficient have through capital current fund the expect plan we to that operating

XXXX. XXXX, compared in million million R&D was QX QX $X.X to $X.X Our expense in

Our G&A $X.X of in million expense of XXXX. third was quarter compared the XXXX, quarter million the third in $X.X to

QX Our operating in million $XX.X compared XXXX, loss QX was $X.X XXXX. million to in

Our net QX. loss was in per share $X.XX or $X.X

XXth, shares outstanding September XX.X shares of common million had of outstanding on XX we XXXX, as-converted As and common basis. million an

back Additional financial I be we will over after XX-Q the information available file which pass the in Jill. our call SEC today. with now will market to

Jill Milne

upcoming the expected Slide the as their and HAE Noah. what needs understand better you, the for to patient We we listen outlines envision XX of unmet Astria this Astria. community the at do. guides voices Thank milestones to we future

a for infrequent a of life HAE patients, dosing. one a for are efficacy meaningful with preventative with better long-acting therapy opportunity path We an has new that charting envisions that quality

are our We addressing broader evaluating patients. the a opportunities expand there, stopping unmet also we not are to pipeline with needs goal of of

to Our and the the currently poll develop boundaries bring rare therapeutics care by repeat standard please patients’ Operator, I’ll what lives operator immunology. to for Thank to niche the of meaningful goal that, as can call questions. your ask instructions and With for the allergy the of you is you. pushing perceived is and in changes questions. that diseases open for

Operator

Instructions] first the Oppenheimer. of line go Singh of from question Your Hartaj ahead. Please comes Certainly. [Operator

Hartaj Singh

great Great, here, – nice and team. thank you. Thank the you for presentation Jill

X few three I’m your to antibody Could give some you serve Just some about you’d a doing over. sure switch in on study versus kind time know of get full what’s between half-life terms X around two, Could a meaning market the as type that you accelerated you for between patients’ and And you you or Phase you. aside much be you a would your markers some there’s versus one, X you of the a sort So to findings what That’s quick know showing you’re relationship of of you of sort Could number for time inhibition also possible Phase if that tax number mind. know know, study? those Phase research, you Phase up of months, and little you’ll your then from plasma couple looking is, you know kallikrein. X/X kind go indicated plan? of have a questions. for approval you the increasing biomarkers quite you One a as attacks need dosing? like between the color know that, more decreasing in there increasing know in color balance as could patients physicians’ Thank doses? decrease bit you

Jill Milne

Thanks, Hartaj.

address anything me can start Andrew have out if well left on I both anything contribute research Let side market contribute questions. the as see if and your areas the And I’d of certainly out. I’d that if Andy left and

in So biomarkers general. the first, the you Phase about asked design X and

absolutely and important, and incorporating of understand right, in level to helping you’re we of Xb/X the level beyond plasma achieving. the study we’re markers to So our Phase us we path are that is chart understand see pharmacodynamic do into that Phase is inhibition our inhibition our that X kallikrein of

our and and optimizing it certainly been that data you clinical rare a be and on go we’re known to into understood be X. the has generating a that previously and know registration a Phase and program I at to path will you good done in based is diseases as what think in terms you – we looking know, regulatory of HAE in this get know, is space relatively

be months. in And on and clinical providing regulatory updates certainly so, our the strategy coming we’ll additional

think as what and do disease market is patients and there I and from about we’ve question burden. patients that, In learned terms your burden want of did research well the what’s important decrease as think treatment we learn to here I physicians, – is and

HAE comments. have to Andy able with with a by we’ve we differently efficacy, of to to that I’ll and have And infrequent and for but in clinically. so work we add dosing, really, the think important that be to patients profile clinic could HAE, to to – with it’s really We moment game-changer patients XXX we certainly hope achieve with ourselves establish to robust a get supported both see pause really frequency a and could do for long dosing. and think to that hope reduce a and allow product for of of or attacks to be Andrew that anything live And that time, durations if a this to do want to lot the those infrequent

Andy Nichols

working expeditious the been at Only moment. to include explore to say not approval could is an to approval that path the that accelerated certainly we whether with pathway clear were certainly regulators most

Andrew Komjathy

their only to thing that research market add The and they’re controlling make patients the first is, want it very that foremost I’ll on really was sure clear disease.

So, convincing three is. if could important. level can you very maintaining along the efficacy obviously go, treatment burden that a there, reduce then that to of further the up of high months, is And more you from

that just to I of to the both benefits. providing to of forward elements So, would you those those about say make need that, that’s of providing you physicians you’re possibility both XXXX really excited talk what that and the treatment sure we know going

Hartaj Singh

Yeah, you. Thank great.

preclinical know suggest got lead of Your balance. you some good you’ve profile

So the thank you questions. for

Jill Milne

Thank Hartaj. you,

Operator

from comes with the go question Please ahead. next of Suji Jefferies. line Jeong Your

Suji Jeong

progress And question all thanks Hi, for made. and that the my congratulations on guys morning. you good taking

questions for STAR-XXXX. couple of say, about a have development I So the timeline clinical

has said period you’re that the a the to looking patients longer drug long you time. since of in half-life follow the for So presentation,

follow-up Phase to X I from questions. when and that So from was you data plan interim the by present what end full to patients? do data next you And type year, X you of just data expect Phase of present how data I have from when the many the and a have wondering

Jill Milne

Suji. you, Thank Right.

and start Andy finish. with me Let let that

Phase year the to we of an timeline, file that end so and soon have XXXX thereafter. Xa end year, track from development initial clinical year IND are results volunteers just our by Phase to healthy XXXX. on mid reiterate We’ll next study So, initiate in Xa in normal

for we believe be time collect long data also that that well appropriate we’ll absolutely will half-life you’re XXXX. the patients that and data, initial in will maybe to that, the terms and in extended a of initial that. profile hand expect this to half-life following that data have plasma a differentiated end And STAR-XXXX But And we period what half-life demonstrate hope it we of those establish is to very a profile. we human with and the initial XXXX long be we of volunteer that that hope healthy kallikrein in long patients antibody we at comment inhibition with safety from that year very to asked see to into those STAR-XXXX. You support normal pharmacokinetic on I’ll so following Andy data differentiated will be to right,

Andy Nichols

Yeah.

what of our cohorts it say in to is and that it at will extended by activity first could XXX has necessarily extended pharmacodynamic we to the and the to definitively the year of that effective. fact, of be cohorts, sort not from to the from able end So that of have data Because XX least be estimate calculate half-life data the is couple allow in the is pharmacologically first of to half-life doses but able us couple and pharmacokinetic that expectation day range. pharmacologically to to

adequately to And able product. to the be up the follow safety to to patients will of We year. the important exposure profile during have a assess for

stop at that from based is set but decisions looking collecting. be So, it will this does study, the from will we not making and that actually the initial extended of available on take data earlier an us full data before period time

Jill Milne

development an about around STAR-XXXX. our X about the design asked you update months And numbers. clinical We more the hope the Phase and in to the hopefully coming patient for details details give full program about

Suji Jeong

sometime be would update early next year? that So

Jill Milne

we to imagine folks believe on next year going and available where at refining Yeah, and what make to forward months, it that as want expect know you let to might year end to the in publicly the expect plan with program. coming what actively working

Suji Jeong

I see.

was? the you long So half-life how say did

Andy Nichols

XX that day monoclonal the other humans. have as While YTE have the extension estimate range antibodies modifications half-life is same XXX in demonstrated the and the from half-lives technology, they to

you for initial actually follow to months, So three in volunteers we half-lives follow the an dosing the patient X have days, you Phase XX X average have about study. actually so the from three half-life months to the of could – if multiple would Phase imagine and – is the people

possibly So, up to nine months. probably months XX at least

Suji Jeong

see. I

So Phase still in intact? plan XXXX, is Xb to start your

Jill Milne

still So our plan is intact.

clinical We’re plan now by also the regulators our that Xa. be data going will will informed that a our refining the from development obviously right X be initial with and into Phase that and and discussion Phase data

Suji Jeong

expect when last should business update Okay. question And I have is, we to hear activity? on the development

Jill Milne

Yeah.

we in So niche, talk be and we hope coming area diseases. the opportunities intend actively immunological pipeline the to in expand explore. evaluating our months and that We are opportunities to of rare allergic to able to about other

Suji Jeong

really you. was that helpful. Thanks, Thank

Jill Milne

Thank you.

Operator

Securities. Wedbush of Chico Please Laura go from comes ahead. question next Your

Laura Chico

for morning taking actually survey that on circle thanks mentioned. wanted burden back the question. to guys, good patient the I Hey, you

stand more indicated general, a there? just effectiveness. therapy the specific still of for why there data attributes they’re on to the understand preventive patients I And differentiation? of you disease that kind shows – are know just trying on might Thanks. of bit is curious that if concern could XXXX about little just most or prophylactic as important have therapy, clinical studies So of any out efficacy clinical more if it I’m those attributes than kind I’m the and wondering just I’m what about same concern latter demonstrate to you You XXXX or elaborate when or issues? concerns that avoid how is in is kind having something to

Jill Milne

let Andrew. it Yeah, and start me then to hand

these think point. about level high and fear I an patients attack. And of great a a live potential anxiety that’s So generally of the with

these be one of the to STAR-XXXX that for clinically think a kallikrein for hope to having profile by patients thing you hope potencies is longer action. that I through inhibitor potent know, duration able that we a we retains in plasma support that

that time. kallikrein maintain three attacks So for we longer up to of prevents hope of periods between level doses months to know plasma for of a occurring you from inhibition

patients So this our in alleviate and this help and thinking any But comments. for add a they would stress disease. over I’ll benefit everyday real additional lives be of their about Andrew be some to hope could lived with anxiety that and hand it to that

Andrew Komjathy

for Sure. question. And you thank the

obviously as with treatments, know these challenge think know that’s especially with experience that, here attacks well speaking you frequency of advent think do both I and news We’re in life-threatening. reduce patients. can the some those you attacks a is and with of learning treatments for preventative The good do physicians But, lot patients. many the of still laryngeal of this, they encouraging I be attacks is as that attacks

the or as So, burden effectively of in STAR-XXXX, reduce make but that as we think to to here three attacks I we with by combination by administration treatment the with sure then up prevent that frequency reduce that frequency of months. is goal can extending can the

So, facing that being again, that treatments think deal I could on these anxiety still they just patients be the knowing it’s with, attacks. still preventative

Laura Chico

I’m quick to to changing with to data competitive And an the you. asked. And have wondering helpful. now if apologize I certainly what But do evolution Thank a as speak Okay, are different in meeting advancing? modalities how Phase was could you agents. where this oral there you antibodies But therapy. think some there at related bit of probably you. prophylaxis? kind little you competitor best been landscape antisense these maybe prophylactic the just suited we Thank follow-up and if I space and that’s X envision modalities one And super view a has recent what been

Andrew Komjathy

Jill. to take that me want You ahead, go –

Jill Milne

Yeah.

in there now more think I – modalities coming. use absolutely right, and multiple in different term right So you’re are

So, you monoclonal STAR-XXXX. the like we have antibodies know

that is I mentioned, that modality presented the last ACAAI for STAR-XXXX preventative in able treatment You attacks we with in the we’ve demonstrate this in from What currently the yet at of that which data in think HAE types of week, with using different was differentiated form very dosing. that we file in that’s that what effective and as very terms of antisense hope at is, a week what’s antibody modality that showed the suggest and candidates pipeline in coming a trusted well in four modalities we’re development. here point another the see reduction every as different percent monoclonal are to on profile been market preclinically

form trusted therapy modality being profile once make a antibody a a every of with we the that could months preventative in believe we really you think difference landscape. in highly so, differentiated the know monoclonal And longer STAR-XXXX could support dosing significant or three

Laura Chico

Thanks Super helpful. very much.

Jill Milne

Laura. Thanks, Great.

Operator

H.C. ahead. comes Your of Please Joe next from question Pantginis Wainwright. go

Joe Pantginis

pipeline to expansion Jill, back I end your potential comments prepared start the on opportunities. the about of wanted

niche could take you’re the to and orphan would forward on with at looking be to you regard marketed were regard opportunities in you bag? your types same at assets own, to be of are flexible more If indications? that sales with Or you XXXX the looking

Jill Milne

the somewhat reasons Yeah, that make work you I and know, we’re a where Yeah, will we related space thanks that. if a be suggest. for and the know We’d to that certainly question. to we We’ll for you organization in to think you pipeline, optimize a on going stay consider significant difference you could know, so we certainly the be like there that But a opportunities of the we’re as in we makes for sense lot us. will we just for probably want was allergy space opportunistic, for patients. great say building that immunology opportunity

Joe Pantginis

You know obviously. that for I that. And XXXX sense. guess makes switching Thanks to

CDMO I it ask What like seems at do your step way. You your and It provided chain to point? global obviously to had for with having ready you of any constraints? enabling would the I guess prepare go. you’ve you to a regard your on and drug long-list IND guess this consider experiencing rate-limiting things board issues activities But all I supply are this or is

Jill Milne

Yeah, a question. that’s great

So, can large efficiently could in we you XXXX trying track know that in remain sure that’s of think potential we ahead we that. arise. well working well of with we get as IND because making are are issues. Right issues And potential are any of well advance that any part to and to to as now that everyone, ahead in we’ll mid on for as

any preparing IND very the and proof-of-concept just prevent clinic that physician studies many get up we initial to companies ours, from that and into we get to doing clinic issues to want between far are like so, enabling try the the other advance for time And and is, in things and and cropping now data. to

Joe Pantginis

question don’t And Got you my it’s data have experiment it. is, got if truly speculative last it, don’t hasn’t you the mind. I and guess been point, at this done. because human

increase once you know field dose? get would you might dosing, every and – the at certain occurrence you you that to would that are that go be assume forward with closer to were for breakthrough next rates do you least rates were there breakthrough with assume one, attacks’ three-month those in as the you attacks projecting to there if anticipate So

Jill Milne

That’s STAR-XXXX, is reduce is want occurrence to profile the we on be something longer, question, every possible. but to support because to certainly the ability that what good dosing the able develop that the we and it target frequency to dosing our mind or for a as greatest of to product level do attacks three and months base on refine to

So, you’re in informed by be will this absolutely patients. data right, the

something to clinical our so be thinking dosing the And at of on dosing look and design in the But is to attacks we’re be right spot patients what is. and those breakthrough that we we going frequency and going so go-forward minimize occurrence optimize that’s can what design we data the as the to think the about. we studies out-front that’s frequency to that’s dose as hope

Joe Pantginis

lot Great. guys. Thanks a

Operator

are conference closing for back questions any now There the to no at remarks. Jill further to I like time. this would hand

Jill Milne

you. of you you call support joining our progress Thank the and with We’ll share again keep your you of morning areas continued Astria. we all updated our soon. to for Andrea? as We this and STAR-XXXX other Great, of forward execute on thank program look for company. speaking

Andrea Matthews

days Investor website on Thank you. at That A be concludes will call. our for replay – the XX via page Relations www.astriatx.com. available webcast today’s today

Astria Therapeutics (ATXS) 10 Nov 212021 Q3 Earnings call transcript